

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only.

The thesis, or part of it, may not be reproduced elsewhere without the permission of the Author.

**The aspirin augmented
standardized lactulose mannitol test
as a measure of the ‘health’
of the gastrointestinal tract**

A thesis presented in partial fulfilment of the requirements for the degree
of

Doctor of Philosophy

at



MASSEY UNIVERSITY

Palmerston North, New Zealand

Ivana Roosevelt Sequeira

2015

DEDICATED TO

My father, Roosevelt Franklin Sequeira

30.04.1947 – 23.02.2014

For teaching me to never give up.

I miss you every day.

ABSTRACT

In this thesis, I studied the ‘classical’ lactulose mannitol test for intestinal permeability that has been used to measure the integrity of the intestinal mucosa and thus to provide an index of recovery from inflammatory bowel disease (IBD) and from autoimmune diseases such as coeliac disease. Perusal of the literature indicates that the protocol for the test has not been standardized and a variety of different test protocols have been used. Hence there are differences in the duration of urinary sampling, the doses of the two test probes, the volumes of fluid consumed during the test and the administration of the test during the fasted or fed state. There is therefore a need for a standardized test.

The bulk of the research conducted in this thesis was to develop an optimal protocol with a standardized osmolarity (720 osmol l^{-1}) for the test solution that contained 10 g of lactulose and 5 g of mannitol dissolved in 100 ml of water. Similarly the total fluid intake was standardized to 700 ml. The volumes of fluid consumed over the experimental period were also standardized in order to control for any osmolar effects of the test drink and to hydrate the subjects sufficiently to enable them to produce half-hourly urine samples of a reasonable volume.

The rates of excretion and the timings of the peaks in the excretion of mannitol and lactulose were found to vary over time in healthy subjects. Hence the rate of mannitol excretion peaked during the first two hrs whilst the rate of lactulose excretion peaked at four hrs. The correlation between urinary excretion with intestinal transit times were confirmed using a wireless motility capsule. The work with the wireless motility capsule indicated that the probe sugars were in the small intestine from $2\frac{1}{2}$ - 4 hrs and in the proximal colon from $4\frac{1}{2}$ - 6 hrs following dosage with the test solution. Hence a sample

collected during the 2½ - 4 hr period is best for assessing permeability of the small intestinal mucosa in healthy subjects. The wireless motility capsule also confirmed that the standardized dose of the lactulose mannitol did not influence gastric transit time or that through the small intestine and large intestine. These findings confirmed that the standardized test was determining absorption during transit of the test sugars through the small and the large intestine.

The effect of co-dosage with 600 mg of aspirin in the standardized test was then examined as a means of assessing the effect of a reproducible noxious stimulus on the absorption of the sugar probes. This agent augmented small intestinal permeability to lactulose and decreased its permeability to mannitol. Furthermore dosage with aspirin amplified the effect of a pre-existing adverse stimulus such as smoking. Hence the aspirin augmented test could conceivably be used to ‘unearth’ sub-clinical inflammation. Further work explored the effect of an antioxidant, ascorbic acid, on mucosal permeability. The results showed that, rather than mitigating the adverse effects of aspirin, ascorbic acid augmented intestinal permeability.

In summary the work in this thesis has enabled the development of a standardized test that optimizes the ability of the lactulose mannitol test to detect clinical disorders of absorption. Further, augmenting the test with a single dose of aspirin may be useful as an index of gut health or robustness.

ACKNOWLEDGEMENTS

‘The only limits are, as always, those of vision’ - James Broughton

I take this opportunity to present an unedited gratuitous expression to a few people that deserve special mention for their role in the accomplishment of my thesis.

My ‘academic parents’ here at Massey, Prof. Roger Lentle and Prof. Marlena Kruger, for caring and believing in me even when I doubted myself - your unfailing expectations, unwavering support and guidance helped fuel my determination.

Roger, my ‘gastro *guru*’, has always believed in my abilities. His passion and enthusiasm was often contagious. In reviewing my work and writing, he offered painstaking comments and always respected my voice. His comments and suggestions often evoked a mixture of gratitude (for the detailed attention to my arguments), exhilaration (as he always dramatically improved it!) and awe (“why didn’t I think of that?”). Thank you Roger for ‘damaging my brain’, for always reiterating ‘don’t you worry lass’ and for the constant kind words that motivated me to do better.

Marlena has been the calming influence throughout my work. Had it not been for the consideration that she gave to my application in 2009, a PhD in New Zealand would not have become a reality. As the voice of reason and a solid sounding board she often came up with issues that I would not have otherwise identified. I express my deep gratitude to her for thinking me worthy of this opportunity, for her encouragement and continuous support.

I gratefully acknowledge Dr. Roger Hurst and the New Zealand Institute for Plant and Food Research for the funding received during the course of this project. Dr. Roger

Hurst's advice and guidance during the project has been invaluable. Routine meetings with both Rogers' in attendance have never been dull!

Chris Booth and Michelle McGrath have been more than lab managers associated with the project, but friends whom I could count on and 'go to' when work got the better of me. Also Corrin, Shampa and others that gathered during morning tea, I appreciate the constant encouragement and healthy doses of caffeine you've shared with me. Dr. Gordon Reynolds, Prof. Patrick Morel and Dr. Fran Wolber, whose brain I picked to often review my writing, thank you for your patience with reading and offering me invaluable advice.

In recognition of the lasting friendships that I have made; Merrin, Kenneth, Zirsha, Jerry, Mel, Samuel, Alex, Julia, Matthew and Wensheng thank you for the immense support, constant encouragement and for being there when I needed to let off steam.

My parents, Roosevelt and Lorena, brother Delano and god father Carl have been my pillars of strength and greatest support. Thank you for nurturing my goals and ambitions and supporting me during my strife. Much love to you.

Thank you all for being a part of my journey. The stress, excitement, hard work, sleepless nights and sheer joy at finally feeling like I have made a 'discovery' is unimaginable.

A special mention to 'Damien', the HPLC system, he was steadfast and rock solid when there were very many samples that required analysis!

To all the participants without whom none of the studies would have been possible, I am very grateful. Approval for all research described in this thesis has been obtained from the Massey University Human Ethics Committee Southern A.

TABLE OF CONTENTS

TABLE OF CONTENTS	v
LIST OF FIGURES	xvii
LIST OF TABLES	xx
CHAPTER 1 Overview of the thesis	1
1.1. Introduction	2
1.2. The GI tract - a selective filter to the changing dynamic luminal environment.....	3
1.3. How can we quantify gut ‘health’?	5
1.4. Intestinal Permeability - potential 'dynamic' measure of gut health	6
1.5. Perspective of the thesis	7
1.6. Structure of the thesis	11
1.7. References.....	12
CHAPTER 2 Review of literature	15
2.1. Factors influencing mucosal permeability.....	16
2.1.1. Elements that constitute the barrier property of the intestine	16
2.1.2. The pre-epithelial layer – the first barrier that possibly alters diffusion gradients and rates of absorption	18
2.1.3. The epithelial layer – the barrier that selectively absorbs nutrients via diffusion via the transcellular and paracellular route	20
2.2. Measuring intestinal gut permeability	28
2.2.1. Dual sugar absorption test.....	28
2.2.2. Carbon labelled breath tests.....	37
2.2.3. Paracetamol absorption test.....	38
2.2.4. Cellular methods.....	39
2.2.5. <i>In vitro</i> gut models.....	43
2.2.6. Conclusion.....	44
2.3. Aspirin, a pro-inflammatory mediator that influences mucosal integrity; implications for the sugar absorption test	45
2.3.1. Pharmacology, metabolism and absorption of aspirin in the GI tract.....	45
2.3.2. Chemistry of aspirin and salicylic acid with biomolecules	48
2.3.3. Aspirin induced increase in intestinal permeability	58

2.3.4. Conclusion.....	59
2.4. References.....	60

CHAPTER 3 Development and calibration of an analytical method to quantify excreted sugar probes.....77

3.1. Introduction.....	78
3.2. Methodological development.....	84
3.2.1. Reagents and Calibrators.....	84
3.2.2. Sample preparation.....	84
3.2.3. Optimization of column oven temperatures.....	91
3.3. Chromatographic conditions.....	94
3.3.1. Chromatographic separation.....	94
3.4. Calibration of the method.....	100
3.4.1. Calibration curves with reference solutions of probe sugars.....	100
3.4.2. Calibration with spiked urine samples.....	104
3.5. Testing the sensitivity of the method to detect sugars in urine samples collected in human studies.....	112
3.5.1. Calculating of the dose of lactulose and mannitol necessary to prepare the test solution.....	112
3.5.2. Determining if the calculated dose of lactulose and mannitol is sufficient for them to be readily detected in human urine.....	114
3.6. Conclusion.....	120
3.7. References.....	121

CHAPTER 4 The effect of aspirin and smoking on urinary excretion profiles of lactulose and mannitol in young females: Towards a dynamic, aspirin augmented, test of gut mucosal permeability..... 125

4.1. Abstract.....	126
4.2. Introduction.....	127
4.3. Methods.....	130
4.3.1. General.....	130
4.3.2. HPLC.....	133
4.3.3. Data processing and statistical analysis.....	135
4.4. Results.....	136
4.4.1. General.....	136

4.4.2.	Reliability of the assay.....	137
4.4.3.	Variation in urinary excretion of lactulose, mannitol and LMR with placebo	138
4.4.4.	Variation in LMR and excretion of lactulose and mannitol with aspirin.....	143
4.5.	Discussion.....	147
4.6.	Afterword	152
4.7.	References.....	153

CHAPTER 5 Differential trafficking of saccharidic probes following aspirin in clinical tests of intestinal permeability in young healthy female subjects..... 157

5.1.	Abstract.....	158
5.2.	Introduction	159
5.3.	Methods	162
5.3.1.	Ethical Approval	162
5.3.2.	Subjects and screening procedure.....	162
5.3.3.	Experimental protocol.....	163
5.3.4.	HPLC	164
5.3.5.	Data processing and statistical analysis	165
5.4.	Results	168
5.4.1.	Participants.....	168
5.4.2.	Reliability of the assay.....	168
5.4.3.	Temporal variation in the recovery of the two smaller sugars, mannitol and rhamnose and the larger sugar lactulose.....	169
5.4.4.	Cumulative recoveries of probes	175
5.4.5.	Analysis of the half-hourly rates of recoveries of the probes.....	178
5.5.	Discussion.....	182
5.6.	Afterword	186
5.7.	References.....	187

CHAPTER 6 Assessment of the effect of intestinal permeability probes (lactulose and mannitol) and other liquids on digesta residence times in various segments of the gut determined by wireless motility capsule..... 191

6.1.	Abstract.....	192
6.2.	Introduction	193
6.3.	Method.....	195

6.3.1.	Ethical Approval.....	195
6.3.2.	Selection and screening of subjects.....	196
6.3.3.	Experimental protocol.....	197
6.3.4.	Data processing and statistical analysis.....	199
6.4.	Results.....	203
6.4.1.	Stomach.....	204
6.4.2.	Small Intestine.....	207
6.4.3.	Colon.....	209
6.4.4.	Multivariate comparison of segment residence times.....	210
6.5.	Discussion.....	211
6.6.	References.....	214

CHAPTER 7 Standardizing the lactulose mannitol test of gut permeability to minimize error and promote comparability..... 219

7.1.	Abstract.....	220
7.2.	Introduction.....	221
7.3.	Materials and Methods.....	223
7.3.1.	Use of aspirin.....	223
7.3.2.	Screening and experimental protocol.....	223
7.3.3.	Determination of transit time of the sugars solutions through the stomach and small intestine.....	225
7.3.4.	Data analysis.....	226
7.4.	Results.....	228
7.4.1.	Trends in the percentage recovery of the two probe sugars.....	228
7.4.2.	Determination of retention time.....	229
7.4.3.	Patterns of variation of each sugar within each period.....	231
7.5.	Discussion.....	237
7.6.	Afterword.....	242
7.7.	References.....	242

CHAPTER 8 Ascorbic acid may exacerbate aspirin induced increase in intestinal permeability..... 247

8.1.	Abstract.....	248
8.2.	Introduction.....	249
8.3.	Methods.....	251

8.3.1.	Screening procedure	252
8.3.2.	Experimental protocols	253
8.3.3.	Sample handling and HPLC	256
8.4.	Data processing and statistical analysis	258
8.5.	Results	259
8.5.1.	Effects of administration of administration of ascorbic acid and aspirin (Study 1)	260
8.5.2.	The effect of the timing of administration of ascorbic acid (Study 2)	263
8.5.3.	Comparisons with results from the prior published experiment	267
8.6.	Discussion.....	269
8.7.	References.....	272
8a.	Can the increase in intestinal permeability associated with a pharmacological dose of ascorbic acid be extrapolated to that from dietary sources/intake?.....	276
8a.1	References.....	279
8b.	Does a urine collection period 2½ - 4 hr post dosage optimally assess changes in small intestinal permeability	281
8b.1	Introduction	281
8b.2	Data analysis	282
8b.3	Results	283
8b.3.1	Effects of the administration of ascorbic acid and aspirin.....	284
8b.3.2	Comparisons with results from the prior published experiment	285
8b.4	Discussion.....	288
8b.5	References.....	290
CHAPTER 9	Summarizing discussion and conclusions with recommendations for future research.....	291
9.1.	Summarizing discussion.....	292
9.1.1.	Standardization of the 'classical' lactulose mannitol test.....	292
9.1.2.	Augmentation of the 'classical' test with a single dose of 600 mg aspirin ...	296
9.1.3.	Additive effects on intestinal permeability	297
9.2.	Use of the augmented lactulose mannitol test for future work	298
9.3.	Limitations of the thesis	299
9.4.	References.....	300

APPENDICES	303
APPENDIX 1 Health screening questionnaire used in Chapter 4	305
APPENDIX 2 Systat data output	309
APPENDIX 3 Letter pulished in Neurogastroenterology and Motility	345
APPENDIX 4 Response to letter published in Neurogastroenterology and Motility.....	347
APPENDIX 5 Health screening questionnaire used in Chapter 5	351
APPENDIX 6 Editorial published in Clinical and Experimental Pharmacology and Physiology.....	357
APPENDIX 7 Health screening questionnaire used in Chapter 6 & 8	361
APPENDIX 8 Food avoidance list given to participants in Chapter 6	367
APPENDIX 9 Standard operating procedures for use of the SmartPill data logger used in Chapter 6.....	371
APPENDIX 10 Emergency Card given to participants in Chapter 6.....	375
APPENDIX 11 Diary to record daily 'events' given to participants in Chapter 6.....	377
APPENDIX 12 Standard operating procedures for fecal sample collection given to participants in Chapter 6.....	379
APPENDIX 13 Food avoidance list used in Chapter 8.....	381

LIST OF PUBLICATIONS

Published manuscripts

1. Sequeira IR, Lentle RG, Kruger MC, Hurst RD. The effect of aspirin and smoking on urinary excretion profiles of lactulose and mannitol in young women: toward a dynamic, aspirin augmented, test of gut mucosal permeability. *Neurogastroenterology & Motility* 2012; 24:e401-e11.
2. Sequeira IR, Lentle RG, Kruger MC, Hurst RD. Mucosal permeability testing: response. *Neurogastroenterology & Motility* 2013;25:855-855.
3. Sequeira IR, Lentle RG, Kruger MC, Hurst RD. Differential trafficking of saccharidic probes following aspirin in clinical tests of intestinal permeability in young healthy female subjects. *Clinical and Experimental Pharmacology and Physiology* 2014. 41:107-117.
4. Sequeira IR, Lentle RG, Kruger MC, Hurst RD. Standardising the Lactulose Mannitol Test of Gut Permeability to Minimise Error and Promote Comparability. *PloS one* 2014;9(6):e99256.
5. Sequeira IR, Lentle RG, Kruger MC, Hurst RD. Ascorbic acid may excaerbate aspirin induced increase in intestinal permeability. *Basic and Clinical Pharmacology and Toxicology* 2015. doi: 10.1111/bcpt.12388
6. Sequeira IR, Lentle RG, Kruger MC, Hurst RD. Assessment of the effect of intestinal permeability probes (lactulose and mannitol) and other liquids on digesta residence times in various segments of the gut determined by wireless motility capsule: a randomised controlled trial. In final review. *PloS one* 2015.

LIST OF CONFERENCE PRESENTATIONS

2012

I. R. Sequeira, R. G. Lentle, M. C. Kruger, R. Hurst. (2012) The effect of aspirin and smoking on excretion of lactulose and mannitol in fit young women: Towards an aspirin augmented test of gut permeability. Oral presentation at the *Human Nutrition and Physiology Symposium* Massey University, Palmerston North New Zealand

I. R. Sequeira, R. G. Lentle, M. C. Kruger, R. Hurst. (2012) The effect of aspirin and smoking on excretion of lactulose and mannitol: Towards an aspirin augmented test of gut permeability. Poster presentation at *Physiology 2012* Physiological Society, Edinburgh International Conference Centre. Edinburgh, UK

MEDIA ARTICLES

2014

1. Massey research improves gut permeability test.
Massey News. February 19th 2014
(<http://www.massey.ac.nz/massey/about-massey/news/article.cfm?mnarticle=massey-research-improves-gut-permeability-test-19-02-2014>)
2. Doctoral student gains international recognition.
Manawatu Standard. February 25th 2014
(<http://www.stuff.co.nz/manawatu-standard/news/9760758/Doctoral-student-gains-international-recognition>)
3. Contains sweeteners.
Massey defining NZ. July 14th 2014
(<http://definingnz.com/contains-sweeteners>)
4. Using sugars to test gut health.
Our Changing World. Radio NZ.
(<http://www.radionz.co.nz/national/programmes/ourchangingworld#audio-20161296>)

ABBREVIATIONS

Å	Angstrom
ADP	Adenosine diphosphate
AJC	Adhesive junctional complex
ANOVA	Analysis of variance
AQP	Aquaporin
ATL	Aspirin triggered lipoxin
ATP	Adenosine tri phosphate
AUC	Area under curve
CLO	Camphylobacter like organism
COX	Cyclooxygenase
Cr-EDTA	Chromium labelled ethylenediamine tetra-acetic acid
CV	Coefficient of variation
DC	Dendritic cell
DPPC	Dipalmitoyl-phosphotidyl choline
DHA	Dehydroascorbic acid
ELISA	Enzyme linked immunosorbent assay
FABP	Fatty acid binding protein
FOS	Fructo-oligosaccharide
FTIR	Fourier transform infrared spectroscopy
GALT	Gut associated lymphoid tissue
GHP	Glutathione peroxidise
GI	Gastrointestinal
GLUT	Glucose transporter
GOS	Galacto-oligosaccharide
GST	Glutathione s-transferase
HETE	Hydroxyeicosatetraenoic acid
HPLC	High performance liquid chromatography
IBD	Inflammatory bowel disease

IBS-D	Irritable bowel syndrome with diarrhoea
IFN- γ	Interferon gamma
Ig	Immunoglobulin
IL	Interleukin
iNOS	Inducible nitric oxide synthase
JAM	Junctional adhesion molecules
LAL	Limulus ameocyte lysate
LI	Large intestine
LMR	Lactulose mannitol ratio
LOD	Limit of detection
LPS	Lipopolysaccharide
LTB	Leukotriene B
MAPK	Mitogen activated phospho/protein kinase
MCT	Monocarboxylic acid transport
MD	Molecular dynamic
MLCK	Myosin light chain kinase
MS	Mass spectrometry
NF κ B	Nuclear factor kappa B
NHE3	Sodium-hydrogen antiporter 3
NO	Nitric oxide
NOD	Nucleotide-binding oligomerization domain receptors
NSAID	Non-steroidal anti-inflammatory drug
O/E	Observed to expected
OTC	Over the counter
PC	Phosphatidylcholine
PDA	Photodiode array
PEG	Polyethylene glycol
PG	Prostaglandin
PGE2	Prostaglandin E2

PGHS	Prostaglandin endoperoxidase synthase
PKC	Protein kinase C
PRR	Pattern recognition receptor
RID	Refractive index detector
RMA	Reduced major axis
ROS	Reactive oxygen species
SD	Standard deviation
SE	Standard error
SGLT1	Sodium glucose transporter 1
SI	Small intestine
SIBO	Small intestinal bacterial overgrowth
SLR	Simple linear regression
SOD	Superoxide dismutase
SVCT	Sodium dependent secondary active transport
Tc-DPTA	Technetium-99-labelled diethylenediaminepeptolytic acid
TEER	Transepithelial electrical resistance
TJ	Tight junction
TLC	Thin layer chromatography
TLR	Toll-like receptors
TNF- α	Tumour necrosis factor α
UC	Ulcerative Colitis
UV	Ultraviolet
UWL	Unstirred water layer
WHO	World Health Organization
ZO	Zona occludins

LIST OF FIGURES

Figure 2-1: Schematic representation of two hypotheses presented for the passive diffusion of molecules across the enterocytes..	21
Figure 2-2: Schematic depiction of the apical junctional complex.	23
Figure 2-3: pH-dependent equilibrium of ionized and non-ionized forms of aspirin	46
Figure 2-4: Decreased PG synthesis due to aspirin induced COX inhibition.....	50
Figure 2-5: Role of prostaglandins in the stomach and the effect of aspirin and selective cyclooxygenase 2 (COX-2) inhibitors.	52
Figure 3-1: Sample treatment with Amberlite resin..	86
Figure 3-2: Samples treated with Amberlite resin and buffered with sodium hydroxide.	88
Figure 3-3: Samples treated with Amberlite resin and buffered with glacial acetic acid.....	90
Figure 3-4: Optimization of column oven temperature.	92
Figure 3-5: Chromatographic separation of lactulose and mannitol in standards.	95
Figure 3-6: Chromatographic separation of lactulose and mannitol in samples.....	97
Figure 3-7: Chromatographic separation of lactulose, mannitol, cellobiose and rhamnose.	99
Figure 3-8: Calibration curves for the lactulose and mannitol standards.....	101
Figure 3-9: Calibration curves for lactulose, mannitol, cellobiose and rhamnose standard.	102
Figure 3-10: Analysis of Duphalac solution.	113
Figure 3-11: Resolving peaks of lactulose and mannitol in urine samples.....	116
Figure 3-12: Resolving peaks of lactulose, mannitol, cellobiose and rhamnose in urine samples.....	119
Figure 4-1: Comparison of the effect of the duration of urine collection (first 3 hr, second 3 hr and 6 hr) on the urinary lactulose:mannitol ratio (LMR) in 20 healthy female subjects following consumption of either 600 mg aspirin or a placebo.....	139
Figure 4-2: Variation of excretion of mannitol and lactulose (mg) in urine samples from 20 healthy female smokers and non-smokers at half-hourly intervals over a six hr period following the administration of placebo and 600 mg aspirin.	142
Figure 4-3: Variation of lactulose:mannitol ratio (LMR) in the successive half-hourly urine samples from 20 healthy female subjects following consumption of either 600 mg aspirin or placebo.	144

Figure 4-4: Comparison of the effect of the duration of urine sample collection on the cumulative excretion of mannitol following consumption of either 600 mg aspirin or placebo in 20 healthy female subjects.....	145
Figure 4-5: Comparison of the effect of duration of urine sample collection on the cumulative excretion of lactulose following consumption of either 600 mg aspirin or placebo in 20 healthy female subjects.....	146
Figure 5-1: Polynomial curve fitted to temporal patterns of variation in percentage recovery of saccharidic probes in half-hourly urine samples from 20 healthy female volunteers after administration of placebo and aspirin.....	171
Figure 5-2: Analyses of recovery of ingested dose of the saccharidic probes in 20 healthy female volunteers following dosing with placebo or aspirin during the time intervals between and following peaks in percentage half-hourly excretion of smaller and larger probes.	172
Figure 5-3: Relationship between half-hourly urinary rhamnose excretion and half-hourly urinary mannitol excretion over a 6 hr period after placebo (100 ml water) intake.	179
Figure 5-4: Relationship between half-hourly urinary excretion of mannitol and rhamnose after administration of the placebo to that after aspirin (600 mg) over a 4 hr period.....	180
Figure 5-5: Relationship between half-hourly urinary excretion of lactulose after administration of placebo to that after administration of aspirin (600 mg) over a 4 hr period.....	181
Figure 6-1: Record of variation in pH and pressure over time obtained by a wireless motility capsule in a healthy female after consumption of the placebo solution	201
Figure 6-2: Variation with treatment in overall gastric emptying times determined by the wireless motility capsule in six healthy females.....	205
Figure 6-3: Spectral density of a Fast Fourier transform (FFT) of variation in gastric pressure determined by wireless motility capsule in a single healthy female after consumption of the placebo solution.....	206
Figure 6-4: Variation with treatment in small bowel emptying times determined by wireless motility capsule in six healthy females.....	207
Figure 6-5: Variation with treatment in colonic emptying times determined by the wireless motility capsule in six healthy females.....	209
Figure 7-1: Half-hourly percentage urinary recovery of ingested dose of mannitol and lactulose in 40 healthy female volunteers following dosage with placebo or aspirin.....	230

Figure 7-2: Simple linear regressions of pooled half-hourly percentage urinary recoveries of mannitol and lactulose against time, during period II and period III after dosage with placebo or aspirin, in forty healthy female volunteers.....	233
Figure 7-3: Comparison of calculated 5 hr cumulative recoveries of mannitol and lactulose in forty healthy female volunteers following dosage with placebo or 600 mg aspirin with those reported for subjects with pro-inflammatory conditions i.e. coeliac disease and Crohn's disease	236
Figure 7-4: Comparison of temporal patterns of half-hourly urinary mannitol (mg) excretion from 40 healthy female volunteers with calculated half-hourly glucose absorbed (mg/ ¹ / ₂ hr) based on published blood sugar values of women with non-insulin dependent diabetes and those with normal glucose tolerance	237
Figure 8-1: Variation in recovery of mannitol (% ingested dose) with treatments over 0-3 and 3-6 hr of urine collection in 28 healthy females compared with results of a previous experiment on 40 healthy female participants.	261
Figure 8-2: Variation in recovery of lactulose (% ingested dose) with treatments over 0-3 and 3-6 hr of urine collection in 28 healthy females compared with results of a previous experiment on 40 healthy female participants.	262
Figure 8-3: Variation in the percentage excretion of mannitol in nineteen healthy female subjects with the timing of dosage of ascorbic acid during the first (0-3 hr) and second (3-6 hr) three hours of urine collection.....	264
Figure 8-4: Variation in the percentage excretion of lactulose in nineteen healthy female subjects with the timing of dosage of ascorbic acid during the first (0-3 hr) and second (3-6 hr) three hours of urine collection.....	267
Figure 8b-1: Variation in recovery of mannitol (% ingested dose) with treatments over the 2 ¹ / ₂ - 4 hr of urine collection in 28 healthy females participants.....	284
Figure 8b-2: Variation in recovery of lactulose (% ingested dose) with treatments over the 2 ¹ / ₂ - 4 hr of urine collection in 28 healthy female participants.	285
Figure 8b-3: Variation in recovery of mannitol (% ingested dose) with treatments over the 2 ¹ / ₂ - 4 h of urine collection in 28 healthy females compared with results of a previous experiment on 40 healthy female participants.	286
Figure 8b-4: Variation in recovery of lactulose (% ingested dose) with treatments over the 2 ¹ / ₂ - 4 h of urine collection in 28 healthy females compared with results of a previous experiment on 40 healthy female participants.	287

LIST OF TABLES

Table 2-1: Characteristics of commonly used probes to assess intestinal permeability	30
Table 3-1: Summary of studies using HPLC	81
Table 3-2: Preparation of urine spiked samples for calibration curves.....	104
Table 3-3: Ratio of the observed/expected recovery of the two sugars using 3 spiked urine samples	105
Table 3-4: Recovery of the two sugars from 3 different spiked urine samples	106
Table 3-5: Recovery of the two sugars from 3 different spiked urine samples	107
Table 3-6: Intra-assay variability of the concentration of the 2 sugars in 3 urine samples each repeated 10 times within the same run.....	108
Table 3-7: Intra-assay variability of the concentration of the 4 sugars in 3 different spiked urine samples each repeated 10 times within the same run.....	109
Table 3-8: Inter-assay variability of the concentration of 2 sugars in 3 urine samples each repeated 10 times in consecutive assays	110
Table 3-9: Inter-assay variability of the concentration of 4 sugars in 3 different spiked urine samples each repeated 10 times in consecutive assays	111
Table 3-10: Manual method of integration of urine samples following the baseline correction, using the LC solutions software, to accurately quantify the lactulose peak.....	117
Table 4-1: Variation in urine volumes between smokers and non-smokers receiving either placebo and aspirin over the period of sampling.....	132
Table 4-2: Differences in the quantities of lactulose, mannitol and cumulative LMR between smokers and non-smokers after receiving either placebo and aspirin in urines collected over the first three hrs, the second three hrs and the entire six hr period	140
Table 5-1: Comparison of the peak defined segments of the temporal pattern of variation of excretion of the three sugars in 20 healthy female volunteers, showing variation of slopes of segments on simple linear regression.....	174
Table 5-2: Comparison of the peak defined segments of the temporal pattern of variation of excretion of the three sugars in 20 healthy female volunteers, showing variation in peak mean values between treatments	174
Table 5-3: Cumulative recoveries of lactulose, mannitol and rhamnose in urine samples expressed as the percentage recovery of the ingested dose.....	176

Table 5-4: Variation in the percentage excretion of urinary lactulose, mannitol and rhamnose over collection periods of differing duration in 20 healthy female participants.....	178
Table 6-1: Characteristics of the various treatment solutions	198
Table 6-2: Variation in pH over four equal consecutive quartiles of small intestinal residence time	208
Table 6-3: Variation in pH in the initial and latter half of the colonic residence time with various treatments	210
Table 6-4: Results of Principle component analysis of gastric, small and large intestinal transit times	211
Table 7-1: Comparison of results of simple linear regressions from period II and III in the temporal pattern of excretion of lactulose and mannitol in 40 healthy female participants	232
Table 7-2: Variation in calculated hourly percentage excretions of urinary lactulose and mannitol with duration of collection period and consequent change in the lactulose:mannitol ratio (LMR) based on data from 40 healthy female participants.....	235
Table 8-1: Experimental protocol of study 1	254
Table 8-2: Experimental protocol of study 2.....	255
Table 8-3: Variation of cumulative urinary excretion of lactulose and mannitol (% ingested dose) and LMR with time and treatment in Study 1	260
Table 8-4: Variation of cumulative urinary excretion of lactulose and mannitol and LMR (% ingested dose) and LMR with time and treatment in Study 2.....	265

